VCEL · Vericel Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Vericel posted Q2 revenue of $77.5M (up 22%) driven by MACI (+23%) and Burn Care (+22%), delivered $2.2M GAAP net income and $14.3M of free cash flow, raised full-year 2026 revenue guidance to $330–$340M and authorized a $200M share repurchase program.
- + Q2 total revenue grew 22% to $77.5M, above guidance, driven by MACI up 23% and Burn Care up 22%.
- + Company raised full-year 2026 total revenue guidance to $330–$340M and raised MACI and Burn Care guidance.
- + First-half 2026 results were strong with 26% total revenue growth, 47% adjusted EBITDA growth and nearly $30M of free cash flow.
- + NexoBrid posted record quarterly revenue of $1.5M+, up 30%+ year-over-year and quarter-over-quarter, with record ordering centers and hospital units.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCEL
this stock
Vericel Corp
|
$2.03B | +11.5% | +16.5% | 82.7 | 10.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCEL | +3.5% | -0.9% | +19.5% | +0.6% | +11.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +4.2% | -1.0% | +7.3% | +1.2% | -0.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.